Invion logo
IVX
Pharmaceuticals, Biotechnology & Life Sciences

Invion

Short interest
0.01%
+0.01 pp 30d
as of 11 Feb 2025
Reported shorts
8.5K
Shares on issue
70.356M

Invion (IVX) financials

Results, ratios and statements

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue
$384.7K (source: ASX (Markit))vs $0 (source: ASX (Markit)) (FY25)
ASX (Markit), as at 14 Oct 2026
NPAT
−$5.6M (source: ASX (Markit))vs −$8.8M (FY25)
ASX (Markit), as at 14 Oct 2026
EPS (diluted)
−$0.063 (source: Derived: trailing 12 months at year end)vs −$0.12 (FY25)
Derived: trailing 12 months at year end, as at 14 Oct 2026
Rev YoY
n/aFY
EPS YoY
n/aTTM
  • ASX (Markit)
  • Derived: trailing 12 months at year end

Summary of Appendix 4E and Annual Report, 26 Aug 2026

Invion Limited reported revenue of $384,707 for FY2026, with a net loss of $5,632,977, a 36% improvement from the prior year's loss of $8,807,732. No dividends were paid or declared. The company advanced its PhotosoftTM technology, securing an expanded global license, a South Korean government grant, and FDA Orphan Drug Designation for INV043.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026

Gross margin
100.0%
Operating margin
−1,472.2%
Net margin
−1,464.2%
FCF margin
−634.9%
ROE
n/a
ROA
n/a
FCF conversion
n/a
Net debt (excl. leases)
n/a
Net debt / EBITDA
n/a
Current ratio
n/a
Interest cover
−16.3×
Cash dividends paid / net profit
n/a
Market cap
n/a (no share count we can vouch for)
P/E
n/a
P/B
n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 14 Oct 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

IVX income, newest period first, figures in AUD
Line itemFY26FY25FY24FY23
Revenue$384.7K (source: ASX (Markit))$0 (source: ASX (Markit))$3.7M$4.1M
Gross profit$384.7K (source: Derived: trailing 12 months at year end)n/a$3.7M$4.1M
Operating income−$5.7M (source: Derived: trailing 12 months at year end)−$8.1M−$5.4M−$1.6M
EBITDA−$3.6M (source: Derived: trailing 12 months at year end)−$3.3M−$4.6M−$965.4K
EBIT−$5.3M (source: Derived: trailing 12 months at year end)−$8.1M−$5.4M−$1.6M
Interest expense$346.8K (source: Derived: trailing 12 months at year end)$694.8K$240.0Kn/a
Pretax income−$5.6M (source: Derived: trailing 12 months at year end)−$8.8M−$5.6M−$1.6M
Tax$0 (source: Derived: trailing 12 months at year end)$0$0$0
NPAT−$5.6M (source: ASX (Markit))−$8.8M−$5.6M−$1.6M
Net interest income−$346.8K (source: Derived: trailing 12 months at year end)−$694.8K−$240.0K$33.6K
EPS basic−$0.063 (source: Derived: trailing 12 months at year end)−$0.12−$0.090−$0.030
EPS diluted−$0.063 (source: Derived: trailing 12 months at year end)−$0.12−$0.090−$0.030
Sharesn/a84.9M66.0M64.2M
  • ASX (Markit)
  • Derived: trailing 12 months at year end